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Objective. To conduct a comprehensive PRISMA-compliant systematic review and meta-analysis to evaluate the efficacy and safety
of Chinese medicines (CMs) as an adjuvant therapy for unresectable HCC during transarterial chemoembolization (TACE).
Methods. Main databases were searched up to October 2012 for randomized controlled trials (RCTs) evaluating the effects of
CMs plus TACE on unresectable HCC compared with TACE alone. References of relevant reviews and eligible studies were also
assessed. Risk ratios with 95% confidence intervals and mean difference were calculated. Heterogeneity and publication bias were
examined. Results. Sixty-seven trials (N = 5,211) were included in the meta-analysis. Sensitivity analysis and random-effects model
were performed for assessing significant heterogeneity. CMs plus TACE showed beneficial effects on tumor response, survival at
6, 12, 18, 24, and 36 months, quality of life, and TACE toxicity reduction compared with TACE alone. Conclusion. The results show
that the use of CMs may increase the efficacy and reduce the toxicity of TACE in treating patients with unresectable HCC. These
findings suggest that CMs could be considered as an adjuvant therapy for unresectable HCC patients during TACE. Larger-scale
RCTs using standard methods and long-term follow-up are warranted to confirm these findings.
1. Introduction
Liver cancer, mainly hepatocellular carcinoma (HCC), ranks
the sixth most common cancer and the third leading cause of
cancer-related death worldwide [1, 2]. Annually, more than
748,000 new cases are diagnosed and 695,000 died with liver
cancer. HCC is mostly unresectable as many were detected
at advanced stage with poor liver function, high tumor
recurrence rate, and metastasis [3]. As most HCC patients
are not suitable candidates for curative resection, transarterial
chemoembolization (TACE) is the most commonly used
for unresectable HCC patients as a primary and palliative
therapy because of improvement in survival [4–6]. However,
severe side effects including liver and renal failure, bone
marrow depression, postembolization syndrome, and liver
abscess were observed with the use of TACE [4, 7].
Chinese medicines (CMs) were commonly used in treat-
ing HCC with side effects seldom reported. Increasing num-
ber of studies was conducted in assessing the effects of CMs
on HCC. Experimental studies found the chemopreventive
effects and anti-HCC properties of CMs mainly through the
induction of apoptosis and autophagy and cytotoxicity on
cancer cells [75–78]. Although three systematic reviews eval-
uating the efficacy of CMs on HCC had been published [79–
81], the effect of CMs combined with TACE in treating HCC
remains uncertain. No systematic review was conducted
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according to the preferred reporting items for systematic
reviews and meta-analyses (PRISMA) [82]. Moreover, two
of these reviews included nonrandomized controlled trials
which probably overestimated the beneficial effects of CMs
[79, 81]. Another review had not focused on specific stage
of HCC [80]. In addition, a significant proportion of related
randomized controlled trials (RCTs), especially those pub-
lished recently (2007 afterward, 27 studies), were not included
in these reviews. Therefore, we conducted a comprehensive
and PRISMA-compliant systematic review andmeta-analysis
to investigate the efficacy of CMs on unresectable HCC
including updated trials published after 2007. Specifically, we
aim to critically appraise the efficacy and safety of CMs as an
adjuvant therapy for unresectableHCCpatients duringTACE
treatment focusing on outcomes of survival, tumor response,
quality of life (QoL), and TACE toxicity.
2. Methods
This systematic review was conducted according to the
PRISMA statement [82].
2.1. Search Strategies. Main electronic databases includ-
ing MEDLINE (1946–2012), EMBASE (1947–2012), AMED
(1985–2012), CINAHL Plus (1937–2012), PubMed (Jan-
uary 1966–2012), the Cochrane Library (1996–2012), Chi-
nese Biomedical CD Database (CBM, January 1980–2012),
ChinaNetworkKnowledge Infrastructure (CNKI, 1911–2012),
TCMOnline (1949–2012), ChineseMedical Current Contents
(CMCC, 1994–2012), and WanFang Data (1989–2012) were
searched for eligible studies. The latest search was performed
on October 2012. References of relevant reviews and eligible
studies were also checked.
The search terms used were “liver cancer,” “hepatocellular
carcinoma,” “primary liver carcinoma,” “Chinese medicine,”
“herbal medicine,” “traditional medicine,” and “complemen-
tary medicine” without restriction on publication language
and publication type. Free-text and MeSH terms were used
when allowed. The search strategies in Chinese and English
were slightly adjusted to suit the instructions of different
databases.
2.2. Study Selection Criteria. Eligible RCTs examining the
efficacy of CMs plus TACE in treating unresectable HCC
were assessed. Inclusion criteria were as follows: (a) RCTs;
(b) participants in treatment group received combination
therapy consisting of CMs and TACE and TACE alone in
control group; (c) participants had unresectable or stage II
or above primary HCC which were confirmed by cytological
or pathological results, or met the criteria of the European
association for the study of the liver guideline; (d) reported
data on at least one of the outcomes including survival, tumor
response, QoL using the Karnofsky performance scale (KPS),
or TACE-related toxicity.
Primary outcomes were 6-month, 12-month, 18-month,
24-month, and 36-month survival and tumor response.
Secondary outcomes included KPS (QoL) and TACE toxicity.
Survival was defined as the number of patients in each
intervention group who were alive at 6, 12, 18, 24, or 36
months. Tumor response has to be assessed using the World
Health Organization (WHO) criteria, which were commonly
used to evaluate therapeutic efficacy on solid tumors [83, 84].
According to the results of CT and/or MRI, the efficacy of
anticancer agents was classified as follows: complete response
(CR) refers to the disappearance of all visible tumor lesions;
partial response (PR) refers to 50% or more decrease in
the lesions; no change (NC) refers to either less than 50%
decrease in total tumor size or at least 25% increase in the
lesions; and progressive disease (PD) refers to at least 25%
increase in the size of the lesions. Tumor responsewas defined
as CR plus PR and compared before and after treatment.
TACE-related toxicity including gastrointestinal and bone
marrow toxicities was evaluated using the 5-pointWHOscale
(grade 0–4) on reporting acute and subacute toxic effects [85].
Exclusion criteria included the following: (a) using other
complementary medicines in treatment or control group; (b)
metastatic HCC; (c) inconsistency of reporting on methods,
results, or both; and (d) duplicated or redundant publications.
2.3. Study Selection. All searched titles and abstracts were
screened independently by two authors (Fan Cheung and
XuanbinWang) according to the predefined eligibility criteria.
Disagreements were resolved by consensus or consulting a
third author (Yibin Feng). Full texts of the potentially eligible
studies were retrieved and further assessed by these two
authors (Fan Cheung and XuanbinWang) using the same
method.
2.4. Data Extraction. Data of the included studies were
extracted independently and cross-checked by two authors
(FC and XBW) using a standardized extraction form which
was generated at the protocol stage.The extracted items com-
prised (1) authors and year of publication; (2) study design;
(3) participant characteristics; (4) intervention details, and
(5) outcome measures.
2.5. Study Quality Assessment. Study quality was indepen-
dently evaluated by two authors (Fan Cheung and Xuanbin-
Wang) using the six dimensions of Cochrane “risk of bias”
assessment [114]. The assessment criteria included sequence
generation, allocation concealment, blinding, incomplete
outcome data, selective outcome data, and other bias. Each
dimension was rated as “yes” (low risk of bias), “unclear”
(unclear risk of bias), or “no” (high risk of bias). Studies with
3 or more “yes” were classified as high quality with low risk
of bias and 0–2 poor quality with high risk of bias. As bias
of blinding may be more severe for subjective outcomes (e.g.,
QoL) than for objective outcomes (e.g., survival and tumour
response), separate analyses for different outcomes were
conducted as recommended by Cochrane collaboration [114].
2.6. Statistical Analysis. Review Manager 5.1 (The Nordic
Cochrane Centre, Copenhagen, Denmark) was used for data
analysis. Risk ratios (RRs) with 95% confidence intervals
(CIs) and mean difference (MD) were calculated for dichoto-
mous and continuous data, respectively. Heterogeneity was
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Identification
Screening 
Records after removing duplicates: 
Eligibility
Full-text articles assessed for eligibility: 
Included
Studies included in meta-analysis: 
Potentially relevant article records: 
1514 records excluded
Irrelevant with Chinese medicines/ 
330 full-text articles excluded
Intervention, participant, outcomes not 
n = 1911
n = 397
n = 67
n = 2802
Narrative/systematic reviews: n = 243
Nonclinical trials: n = 459
hepatocellular carcinoma: n = 415
No control group: n = 18
Not meeting the inclusion criteria: n = 379
Non-RCTs: n = 101
according to inclusion criteria: n = 225
Incomplete outcome data: n = 3
Duplicate publications: n = 1
Figure 1: Flow diagram of the study selection for this systematic review.
assessed using 𝑋2 test and 𝐼2 statistic with 𝑃 < 0.1 or 𝐼2 >
50%was treated as substantial heterogeneity [114]. Significant
statistical heterogeneity was further assessed using sensitivity
analyses and results were estimated using random-effects
model. In contrast, a fixed-effect model was used for homo-
geneous studies. Publication bias was examined using funnel
plots [115] and Egger’s test [116] (STATA 10.0, StataCorp LP,
College Station, TX, USA). 𝑃 values lower than 0.05 were
considered statistically significant.
3. Results
A total of 2802 potential trials were identified for this
review, of which 891 were duplicate records and 1514 were
excluded because of narrative/systematic review, nonclinical
trials, irrelevance, no comparison group, or not meeting the
inclusion criteria of this study (Figure 1). The full text of 397
articles was retrieved for further evaluation, of which 330
were excluded for the reasons of not RCTs (𝑛 = 101), not
according to the inclusion criteria (𝑛 = 255), incomplete
outcome data (𝑛 = 3), or duplicate publication (𝑛 = 1).
Finally, 67 RCTs with a total of 5211 patients (study sample
size ranged from25 to 236) [8–74]were included in this study.
Two of the included studies were retrieved from the relevant
reviews and studies [20, 21].
3.1. Study Descriptions. All studies were conducted in hos-
pital settings in China, of which 6 were multicentre studies
[18, 36, 39, 57, 58, 67] and the remaining were single-centre
studies (Table 1). All studies adapted parallel-arm group
design. Nearly, all studies, except one [18], were published in
Chinese from 1999 to 2011. Participants aged from 18 to 78
years old. Near half (𝑛 = 32) described the enrollment criteria
(diagnosis, inclusion and exclusion criteria).
Three studies used individualized prescriptions according
to traditional CM syndrome patterns [17, 63, 73], while 46
standardized CM formulae including 4 single herbs and 42
composite formulae were tested in the remaining 64 studies.
Ai Di injection (𝑛 = 8) was the most popularly used
standardized CM formula. The duration of CMs treatment
ranged from 14 days to 3 years.
3.2. Methodological Quality. Of the 67 included studies,
only 15 studies reported the methods of allocation sequence
generation, which included using a random number table
[11, 26, 43, 60, 65], drawing of lots [17], shuffling envelops
[28, 56], stratified randomization [30, 63], and referring to
the sequence of admission [12, 49, 64, 69, 70]. The remaining
52 studies described that the participants were “randomly
allocated,” but the allocation procedures were not reported.
None of the studies mentioned the method of allocation
concealment. Twenty studies reporting objective outcomes
were rated as at low risk of blinding bias. Most studies (82%)
reported no significant difference of baseline characteristics.
No study described intention-to-treat analysis. Only 6 studies
[21, 38, 47, 59, 60, 65] reported the information of dropouts,
in which 3 studies [21, 38, 59] provided reasons of withdrawal.
Forty studies were rated as at low risk of bias for incomplete
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Table 2: Risk of bias assessment.
Study Sequencegeneration
Allocation
concealment
Blinding: outcomes
Blinding
Incomplete
outcome
data
Selective
outcome
data
Other
bias
Risk
of bias
scoreSurvival
Tumor
response KPS AE
Ayi and Liu 2011 [8] U U Y Y / Y Y Y U Y 3
Bao 2007 [9] U U / Y / N N U U Y 1
Cao et al. 2005 [10] U U Y / / / Y Y Y Y 4
Chen and Ding 2007 [11] Y U / Y N N N Y U Y 3
Dan et al. 2007 [12] N U Y Y N / N Y Y U 2
Deng et al. 2009 [13] U U / Y N / N Y Y U 2
Dong et al. 2007 [14] U U / Y N / N Y U U 1
Dong et al. 2008 [15] U U Y Y N Y N N U Y 1
Feng 2002 [73] U U / Y / / Y Y U Y 3
Guo et al. 2005 [74] U U / Y / N N U Y U 1
Han 2009 [16] U U / / N / N N Y Y 2
Hou and Lu 2009 [17] Y U / Y N N N U Y Y 3
Huang et al. 2002 [18] U U Y Y / N N Y U U 1
Huang 2008 [19] U U Y Y / N N Y U U 1
Jia et al. 2003 [20] U U / Y / N N Y Y Y 3
Li et al. 2009 [21] U U / Y / N N N Y Y 2
Li 2007 [22] U U / Y N / N U Y U 1
Li and Fan 2008 [23] U U Y Y / N N Y U Y 2
Liang et al. 2005 [24] U U / Y / Y Y U Y Y 3
Liang et al. 2008 [25] U U Y Y N / N U Y Y 2
Liang et al. 2005 [26] Y U Y Y / / Y U Y Y 4
Ling 2010 [27] U U / Y N / N Y Y U 2
Liu et al. 2007 [28] Y U / Y N N N Y Y Y 4
Lu and He 2009 [29] U U / Y N / N Y Y Y 3
Lu et al. 2010 [30] Y U Y / / / Y Y Y Y 5
Lu et al. 2007 [31] U U / Y N N N Y Y Y 3
Meng 2008 [32] U U Y Y N Y N Y U Y 2
Qiao 2010 [34] U U / / N N N U Y Y 2
Shi and Sun 2005 [33] U U / / N / N Y U Y 2
Sun et al. 2002 [35] U U Y / / N N U U Y 1
Tang et al. 2010 [36] U U Y Y N / N U Y Y 2
Tian et al. 2001 [37] U U / Y N / N U Y Y 2
Tian 2006 [38] U U Y Y N U N Y Y Y 3
Wang et al. 2002 [39] U U / Y N N N U Y Y 2
Wang and Cheng 2009
[40] U U Y Y N / N Y Y Y 3
Wang and Yang 2002 [41] U U Y Y / / Y Y U Y 3
Wang et al. 2008 [42] U U / Y / / Y Y U Y 3
Wang et al. 2007 [43] Y U / Y N Y N Y Y Y 4
Wang 2008 [44] U U / Y N / N Y Y U 2
Weng et al. 2008 [45] U U Y Y N U N Y Y Y 3
Wu et al. 2000 [46] U U Y Y / N N Y Y Y 3
Wu 1999 [47] U U Y / / / Y U U U 1
Wu et al. 2003 [48] U U Y Y / / Y U U Y 2
Xu et al. 2006 [49] N U Y Y / / Y U U U 1
Xu et al. 2007 [50] U U / Y N N N Y Y Y 3
Xu et al. 2007 [51] U U / Y / N N U U Y 1
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Table 2: Continued.
Study Sequencegeneration
Allocation
concealment
Blinding: outcomes
Blinding
Incomplete
outcome
data
Selective
outcome
data
Other
bias
Risk
of bias
scoreSurvival
Tumor
response KPS AE
Xue et al. 2002 [52] U U Y Y / Y Y Y Y Y 4
Yang 2010 [53] U U Y / / / Y U N Y 2
Yang 2006 [54] U U / Y N N N Y Y U 2
Yang 2006 [55] U U / Y / Y Y U U U 1
Yi et al. 2008 [56] Y U / Y N N N U N Y 2
Yu and Kang 2010 [57] U U / Y N Y N U N Y 1
Yuan et al. 2010 [58] U U / Y N / N Y Y Y 3
Yuan and Yu 2005 [59] U U / Y / / Y Y U U 2
R. Q. Zhai and H. Y. Zhai
2010 [60] Y U Y Y N N N Y Y Y 4
Zhang et al. 2005 [61] U U Y Y / / Y N U Y 2
Zhang et al. 2007 [62] U U / Y N N N Y Y Y 3
Zhang et al. 2008 [63] Y U Y Y N / N Y Y Y 4
Zhang et al. 2008 [64] N U Y Y N / N Y U Y 2
Zhang et al. 2007 [65] Y U Y Y N Y N Y Y Y 4
Zhang 2011 [66] U U / Y N / N U Y Y 2
Zhang et al. 2000 [67] U U Y Y / / Y Y U Y 3
Zhao and Huang 2005
[68] U U / Y / / Y Y Y Y 4
Zhao et al. 2006 [69] N U Y Y / / Y U U U 1
Zhou et al. 2002 [70] N U Y / / / Y Y Y U 3
Zhou et al. 2010 [71] U U Y Y N / N N U Y 1
Zou 2004 [72] U U / Y / N N Y Y U 2
AE: transarterial chemoembolization toxicity; KPS: Karnofsky performance scale. Y: yes; N: no; U: unclear.
outcome reporting, 5 (7%) at high risk, and 22 could not
be rated due to insufficient information. Thirty-nine studies
(58%) were rated as at low risk of bias for selective outcome
data, 3 (4%) at high risk, and 25 (37%) did not provide
sufficient information to permit judgment. Consequently, 29
studies were assigned as high quality with a low risk of bias
(Table 2).
3.3. Meta-Analysis of Primary Outcomes
3.3.1. Tumor Response (Short-Term Effectiveness). Fifty-eight
RCTs involving 4482 participants reported tumor response
as an outcome for testing the short-term effect of CMs
plus TACE (combination therapy). The combination therapy
was found to be superior to TACE alone in increasing the
short term effectiveness (RR = 1.33; 95% CI = 1.25 to 1.41;
𝑃 < 0.00001) (Figure 2). The fixed-effect model was used to
combine the data, whereas both 𝑋2 and 𝐼2 test suggested a
low risk of heterogeneity (𝑃 = 1.00; 𝐼2 = 0%).
3.3.2. Survival (Long-Term Effectiveness). Thirty-two trials
presenting 3038 participants reported the number of patients
surviving for 6 to 60 months. Survival at 48 and 60 months
were not evaluated as only 1 study [45] reported the results
on this. Significant increases of survival at 6, 12, 18, 24, and
36 months for combination therapy were found with corre-
sponding RRs (95% CI) of 1.12 (1.07 to 1.16), 1.39 (1.31 to 1.48),
1.89 (1.44 to 2.49), 1.75 (1.55 to 1.97), and 2.51 (1.97 to 3.19),
all 𝑃 < 0.00001 (Figure 3). The results were homogenous
although significant heterogeneity was observed for survival
at 18 months (𝑃 = 0.03; 𝐼2 = 63%). However, similar
estimates (RR = 2.52; 95% CI = 1.67 to 3.82; 𝑃 < 0.0001)
and homogeneity (𝑃 = 0.66; 𝐼2 = 0%) were observed in
sensitivity analysis by excluding a study with outlier.
3.4. Meta-Analysis of Secondary Outcomes
3.4.1. KPS. KPS was measured in 36 studies for assessing
the effect on QoL, in which continuous data was reported
in 9 studies (𝑛 = 477 participants) and dichotomous data
(KPS > 10) reported in 27 studies (𝑛 = 2041 participants).
Significant differences in favor of combination therapy were
found for continuous outcome of KPS (MD = 9.12; 95% CI
= 4.17 to 14.07) (Figure 4). Random-effects model was used
as heterogeneity was observed (𝑃 < 0.00001, 𝐼2 = 95%).
Heterogeneity was reduced (𝑃 = 0.03, 𝐼2 = 18%) after
excluding studies with outliers and the significant difference
between treatment and control groups was robust (RR = 3.94;
95% CI = 2.30 to 5.59; 𝑃 < 0.00001).
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Study or subgroup
Ayi 2011
Bao 2007
Chen 2007
Dan 2007
Deng 2009
Dong 2007
Dong 2008
Feng 2002
Guo 2005
Hou 2009
Huang 2002
Huang 2008
Jia 2003
Li 2009
Li 2007
Li 2008
Liang J. X. 2005
Liang 2008
Liang T. J. 2005
Ling 2010
Liu 2007
Lu 2009
Lu 2007
Meng 2008
Tang 2010
Tian 2001
Tian 2006
Wang C. J. 2002
Wang 2009
Wang R. P. 2002
Wang R. P. 2008
Wang 2007
Wang Z. X. 2008
Weng 2008
Wu 2000
Wu 2003
Xu 2006
Xu 2007a
Xu 2007b
Xue 2002
Yang J. M. 2006
Yang X. L. 2006
Yi 2008
Yu 2010
Yuan 2010
Yuan 2005
Zhai 2010
Zhang 2005
Zhang H. 2007
Zhang H. T. 2008
Zhang J. M. 2008
Zhang Q. 2007
Zhang X. Y. 2011
Zhang 2000
Zhao 2005
Zhao 2006
Zhou 2010
Zou 004
Total (95% CI)
Total events
Events
43
17
18
10
2
19
42
5
10
18
17
21
19
12
8
27
13
49
54
28
16
17
18
47
16
8
16
25
21
6
5
10
18
28
17
19
17
20
22
27
16
12
16
37
11
18
18
73
11
22
11
32
8
30
24
26
29
13
1212
Total
54
28
32
35
20
33
67
35
33
36
30
30
34
32
20
64
35
64
75
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34
24
33
75
30
23
36
47
27
30
43
21
30
55
36
30
30
32
40
34
31
28
36
48
31
35
32
116
30
31
31
58
25
50
30
48
32
25
2248
Events
34
8
10
13
1
13
34
4
8
12
9
7
10
8
6
19
6
35
38
24
16
14
11
37
4
6
12
21
19
5
3
11
8
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9
15
9
10
10
19
14
5
13
28
9
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10
53
11
16
11
27
6
25
14
21
21
10
861
Total
54
26
28
35
20
32
66
33
33
36
27
20
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32
16
64
33
57
71
64
36
24
30
73
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20
36
48
30
30
43
22
29
41
44
30
27
20
20
36
31
22
31
48
31
38
30
108
30
30
33
54
24
45
30
46
32
25
2126
Weight
3.9%
0.9%
1.2%
1.5%
0.1%
1.5%
3.9%
0.5%
0.9%
1.4%
1.1%
1.0%
1.2%
0.9%
0.8%
2.2%
0.7%
4.2%
4.4%
2.7%
1.8%
1.6%
1.3%
4.3%
0.5%
0.7%
1.4%
2.4%
2.0%
0.6%
0.3%
1.2%
0.9%
2.1%
0.9%
1.7%
1.1%
1.4%
1.5%
2.1%
1.6%
0.6%
1.6%
3.2%
1.0%
1.4%
1.2%
6.2%
1.2%
1.8%
1.2%
3.2%
0.7%
3.0%
1.6%
2.4%
2.4%
1.1%
100.0%
M-H, fixed, 95% CI
1.26 [0.99, 1.62]
1.97 [1.03, 3.78]
1.57 [0.88, 2.82]
0.77 [0.39, 1.52]
2.00 [0.20, 20.33]
1.42 [0.85, 2.36]
1.22 [0.90, 1.64]
1.18 [0.35, 4.02]
1.25 [0.56, 2.77]
1.50 [0.85, 2.64]
1.70 [0.92, 3.16]
2.00 [1.05, 3.80]
1.79 [0.99, 3.24]
1.50 [0.71, 3.17]
1.07 [0.47, 2.45]
1.42 [0.88, 2.28]
2.04 [0.88, 4.74]
1.25 [0.97, 1.60]
1.35 [1.04, 1.74]
1.17 [0.77, 1.78]
1.06 [0.64, 1.76]
1.21 [0.79, 1.86]
1.49 [0.85, 2.61]
1.24 [0.93, 1.65]
2.67 [1.04, 6.81]
1.16 [0.48, 2.77]
1.33 [0.74, 2.40]
1.22 [0.80, 1.85]
1.23 [0.88, 1.72]
1.20 [0.41, 3.51]
1.67 [0.42, 6.54]
0.95 [0.52, 1.76]
2.17 [1.13, 4.20]
1.30 [0.82, 2.07]
2.31 [1.17, 4.54]
1.27 [0.81, 1.99]
1.70 [0.92, 3.16]
1.25 [0.75, 2.09]
1.10 [0.65, 1.85]
1.50 [1.06, 2.14]
1.14 [0.68, 1.92]
1.89 [0.78, 4.55]
1.06 [0.61, 1.84]
1.32 [0.99, 1.76]
1.22 [0.59, 2.53]
1.50 [0.87, 2.60]
1.69 [0.93, 3.05]
1.28 [1.01, 1.63]
1.00 [0.51, 1.94]
1.33 [0.89, 1.99]
1.06 [0.54, 2.09]
1.10 [0.77, 1.57]
1.28 [0.52, 3.14]
1.08 [0.76, 1.53]
1.71 [1.12, 2.62]
1.19 [0.79, 1.79]
1.38 [1.05, 1.82]
1.30 [0.71, 2.39]
1.33 [1.25, 1.41]
Treatment Control Risk ratio Risk ratio
M-H, fixed, 95% CI
0.05 0.2 1 5 20
Favours control Favours treatment
Heterogeneity: 𝜒2 = 29.83, df = 57 (P = 1.00); I2 = 0%
Test for overall effect: Z = 9.01 (P < 0.00001)
Figure 2: Results of Forest plots of comparison of CMs plus TACE versus TACE alone on tumor response (complete response + partial
response) for HCC patients at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines;
TACE: transcatheter arterial chemoembolization.
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3.6.1 6 months
Ayi 2011
Cao 2005
Dan 2007
Dong 2008
Li 2008
Liang 2008
Liang T. J. 2005
Lu 2010
Meng 2008
Tang 2010
Tian 2006
Wang R. P. 2002
Weng 2008
Wu 2000
Wu 2003
Zhai 2010
Zhang 2005
Zhang H. T. 2008
Zhang J. M. 2008
Zhang Q. 2007
Zhang 2000
Zhou 2002
Subtotal (95% CI)
Total events
3.6.2 12 months
Ayi 2011
Cao 2005
Dan 2007
Dong 2008
Huang 2002
Huang 2008
Li 2008
Liang 2008
Liang T. J. 2005
Lu 2010
Meng 2008
Sun 2002
Tang 2010
Tian 2006
Wang 2009
Wang R. P. 2002
Weng 2008
Wu 2000
Wu 2003
Xu 2006
Xue 2002
Zhai 2010
Zhang 2005
Zhang H. T. 2008
Zhang J. M. 2008
Zhang Q. 2007
Zhang 2000
Zhao 2006
Zhou 2002
Zhou 2010
Subtotal (95% CI)
Total events
3.6.3 18 months
Dan 2007
Lu 2010
Tian 2006
Zhang H. T. 2008
Zhang J. M. 2008
Subtotal (95% CI)
Total events
3.6.4 24 months
Ayi 2011
Cao 2005
Dong 2008
Li 2008
Liang T. J. 2005
Meng 2008
Sun 2002
Tang 2010
Tian 2006
Wang 2009
Weng 2008
Xue 2002
Zhai 2010
Zhang 2005
Zhang H. T. 2008
Zhang Q. 2007
Zhang 2000
Zhao 2006
Zhou 2002
Subtotal (95% CI)
Total events
Events
48
50
29
41
48
44
67
27
46
28
33
22
51
30
22
26
104
30
26
48
42
94
956
34
42
18
11
24
27
38
36
57
25
12
94
26
24
18
11
33
24
19
24
20
22
90
28
17
40
31
25
63
31
964
12
21
12
25
10
80
15
35
8
23
38
9
80
17
5
13
21
13
14
55
21
30
4
11
42
454
Total
54
50
35
67
64
64
75
30
75
30
36
30
55
36
30
32
116
31
31
58
50
118
1167
54
50
35
67
30
30
64
64
75
30
75
118
30
36
27
30
55
36
30
30
34
32
116
31
31
58
50
48
118
32
1516
35
30
36
31
31
163
54
50
67
64
75
75
118
30
36
27
55
34
32
116
31
58
50
48
118
1138
Events
45
42
24
35
38
37
59
22
37
15
29
19
37
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19
22
90
29
21
40
35
86
813
25
30
8
10
14
11
29
20
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17
11
56
9
18
16
4
22
18
16
14
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13
70
22
7
26
18
22
42
25
652
4
11
4
20
3
42
9
24
8
18
24
8
38
3
0
11
5
6
6
37
17
17
0
4
12
247
Total
54
50
35
66
64
57
71
30
73
20
36
30
41
44
30
30
108
30
33
54
45
110
1111
54
50
35
66
27
20
64
57
71
30
73
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20
36
30
30
41
44
30
27
36
30
108
30
33
54
45
46
110
32
1447
35
30
36
30
33
164
54
50
66
64
71
73
118
20
36
30
41
36
30
108
30
54
45
46
110
1082
Weight
2.4%
2.3%
1.3%
1.9%
2.0%
2.1%
3.2%
1.2%
2.0%
1.0%
1.6%
1.0%
2.3%
1.5%
1.0%
1.2%
5.0%
1.6%
1.1%
2.2%
2.0%
4.8%
44.6%
1.3%
1.6%
0.4%
0.5%
0.8%
0.7%
1.6%
1.1%
2.4%
0.9%
0.6%
3.0%
0.6%
1.0%
0.8%
0.2%
1.3%
0.9%
0.9%
0.8%
0.8%
0.7%
3.9%
1.2%
0.4%
1.4%
1.0%
1.2%
2.3%
1.3%
35.7%
0.2%
0.6%
0.2%
1.1%
0.2%
2.3%
0.5%
1.3%
0.4%
1.0%
1.3%
0.4%
2.0%
0.2%
0.0%
0.6%
0.3%
0.3%
0.3%
2.0%
0.9%
0.9%
0.0%
0.2%
0.7%
13.5%
M-H, fixed, 95% CI
1.07 [0.92, 1.24]
1.19 [1.05, 1.35]
1.21 [0.92, 1.58]
1.15 [0.86, 1.55]
1.26 [0.99, 1.62]
1.06 [0.82, 1.36]
1.08 [0.94, 1.23]
1.23 [0.96, 1.57]
1.21 [0.91, 1.62]
1.24 [0.95, 1.63]
1.14 [0.94, 1.37]
1.16 [0.82, 1.64]
1.03 [0.91, 1.16]
1.15 [0.91, 1.45]
1.16 [0.82, 1.64]
1.11 [0.84, 1.46]
1.08 [0.97, 1.19]
1.00 [0.91, 1.10]
1.32 [0.98, 1.78]
1.12 [0.92, 1.36]
1.08 [0.89, 1.32]
1.02 [0.89, 1.17]
1.12 [1.07, 1.16]
1.36 [0.96, 1.94]
1.40 [1.08, 1.81]
2.25 [1.13, 4.48]
1.08 [0.49, 2.38]
1.54 [1.03, 2.31]
1.64 [1.08, 2.48]
1.31 [0.94, 1.84]
1.60 [1.06, 2.43]
1.25 [1.00, 1.57]
1.47 [1.03, 2.09]
1.06 [0.50, 2.25]
1.68 [1.36, 2.07]
1.93 [1.16, 3.19]
1.33 [0.89, 1.99]
1.25 [0.81, 1.92]
2.75 [0.99, 7.68]
1.12 [0.78, 1.60]
1.63 [1.07, 2.49]
1.19 [0.77, 1.83]
1.54 [1.03, 2.31]
1.32 [0.83, 2.10]
1.59 [0.99, 2.54]
1.20 [1.01, 1.42]
1.23 [0.96, 1.57]
2.59 [1.24, 5.37]
1.43 [1.03, 1.98]
1.55 [1.02, 2.36]
1.09 [0.73, 1.63]
1.40 [1.04, 1.87]
1.24 [1.02, 1.50]
1.40 [1.32, 1.50]
3.00 [1.07, 8.40]
1.91 [1.13, 3.23]
3.00 [1.07, 8.43]
1.21 [0.89, 1.64]
3.55 [1.08, 11.70]
1.89 [1.44, 2.49]
1.67 [0.80, 3.48]
1.46 [1.04, 2.05]
0.99 [0.39, 2.47]
1.28 [0.77, 2.13]
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Figure 3: Continued.
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Figure 3: Results of Forest plots of comparison of CMs plus TACE versus TACE alone on 6-month, 18-month, 24-month, and 36-month
survival for HCC patients at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines;
TACE: transcatheter arterial chemoembolization.
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Figure 4: Results of Forest plots of comparison of CMs plus TACE versus TACE alone onKarnofsky score (continuous data) forHCCpatients
at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines; TACE: transcatheter arterial
chemoembolization.
KPS >10 indicated that the results of KPS increased more
than 10 points after treatment. A superior effect on the
improvement of QoL in combination therapy compared with
TACE alone was observed (RR = 1.74; 95% CI = 1.57 to 1.93;
𝑃 < 0.00001) (Figure 5). As the result was homogenous (𝑃 =
0.83; 𝐼
2
= 0%), fixed-effect model was used.
3.4.2. Reduction in TACE Toxicity (Short-Term Effectiveness).
Results of fixed-effect model in 12 studies showed that TACE
toxicity including nausea and vomiting, alanine transaminase
(ALT) elevation, and bone marrow depression were signif-
icantly reduced in treatment groups compared with TACE
alone with corresponding RRs (95% CI) of 0.86 (0.76 to
0.96), 0.61 (0.04 to 0.93), and 0.71 (0.58 to 0.86) (Figure 6).
Heterogeneity was not observed in the analysis (𝑃 = 0.1, 0.47,
0.85; 𝐼2 = 40%, 0%, 0%; resp.). No chronic adverse reaction
was reported in the studies.
3.4.3. CMs-Related Side Effects. CMs-related side effects were
rarely reported. Only 3 studies (4%) [20, 60, 74] reported
low-grade fever (2 cases), dizziness (1 case), gastrointestinal
discomfort (28 cases), andmild skin itch and rashes (3 cases).
These symptoms were generally alleviated or recovered after
symptomatic treatment. No severe side effects associatedwith
CMs were reported in the included trials. The long-term side
effects of the treatment were uncertain as only short-term
effects were measured.
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Figure 5: Results of Forest plots of comparison of CMs plus TACE alone versus TACE on KPS increased >10 points for HCC patients at
middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines; TACE: transcatheter arterial
chemoembolization; KPS: karnofsky performance score.
3.5. Risk of Bias across Studies. Risk of publication bias was
assessed using funnel plot to compare symmetry for all
studies except for one with outliers (Figure 7). Results of
Egger’s test suggested no significant publication bias of the
included studies (𝑡 = 1.99, 𝑃 = 0.051).
3.6. Common Herbs. The top 10 most frequently used herbs
in the included trials were listed in Table 3 together with
the potential pharmacological properties. Although the con-
stituents of the formulae were varied across the trials, there
was a general consensus in diagnosis based on unique
Chinese medicine theory. Reinforcing healthy Qi and blood,
clearing fire toxin, and resolving dampness were the most
concerned therapeutic principles which were associated with
improvement in short-term and long-term effectiveness.
Radix Astragali (Huang Qi) (𝑛 = 35) was the most frequently
used herb in the trials, followed by Poria Cocos, Rhizoma
AtractylodisMacrocephalae, Radix Ginseng, Radix Bupleuri,
Radix Codonopsis, Semen Coicis, Herba Oldenlandia Dif-
fusa, Radix Paeoniae Alba, and Rhizoma Curcumae.These 10
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Figure 6: Results of Forest plots of comparison of CMs plus TACE versus TACE alone on TACE toxicity (grade 1–4) for HCC patients
at middle and late stages. M-H: Mantel-Haenszel estimates; CI: confidence interval; CMs: Chinese medicines; TACE: transcatheter arterial
chemoembolization.
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Figure 7: Funnel plots of (a) tumor response of the included studies and (b) tumor response of the included studies excluding a study with
outlier results.
herbs are worthy of additional investigation to examine the
possible active components for the use in HCC treatment.
4. Discussion
TACE is one of the few therapeutic treatments for unre-
sectable HCC patients. Although CMs are increasingly used
to enhance the treatment effects of TACE and reduce the side
effects, the effectiveness is uncertain as the updated evidence
has not been systematically summarized.
This is the first PRISMA-compliant systematic review
and meta-analysis for examining the efficacy of CMs plus
TACE (combination therapy) in treating unresectable HCC
patients. Sixty-seven studies involving 5,211 participants met
the study selection criteria. The meta-analysis showed that
the combination therapy was significantly better than TACE
alone in increasing tumor response, prolonging survival,
improving QoL, and reducing TACE toxicity. CM-related
side effects were mild and rarely reported in the studies. The
above findings suggested that CMs might play a potentially
beneficial role in assisting TACE therapy to improve tumor
response, survival, and QoL, as well as reduction in TACE
toxicity.
The results are robust as the analyses were based on 67
RCTs with a large sample size of more than 5000 subjects,
and both short-term (tumor response, QoL, and TACE
toxicity reduction) and long-term (survival) effectiveness
were assessed. Although most of the included studies (𝑛 =
66) were published in Chinese, the trials in this review
represent the best available evidence on the efficacy of CMs
as an adjuvant therapy for unresectable HCC patients during
TACE treatment. Moreover, this review was conducted using
comprehensive, rigorous, and PRISMA-compliant methods.
An extensive searchwas conducted forRCTs published before
October 2012. Between-study heterogeneity was further
assessed by sensitivity analysis and random-effects model.
Publication bias was investigated by both visual funnel plots
and Egger’s test.
Considerable variety in the ingredients of the CM formu-
lae was found in this review which might be due to different
TCM diagnosis and the CM practitioners’ personal expe-
rience. However, a common consensus in TCM diagnosis
and treatment principle was observed among the included
trials. According to our review, CM herbs might enhance the
tumor response by inhibiting tumor angiogenesis and cancer
cell proliferation, inducing apoptosis, and increasing immune
response (Table 3).The enhancement of tumor response may
contribute to the improvement of survival. Moreover, CMs
may reduce the acute and subacute adverse reactions induced
by TACE, thus improve the QoL. Further investigation on
the therapeuticmechanism, pharmacokinetics, pharmacody-
namics and their possible active components of the frequently
used herbs could bring new insight into the treatment of
HCC.
4.1. Limitations. Although extensive searches and strict
methods were used to select studies and estimate the effects,
there are several potential limitations. First, only studies
published in English or Chinese were included, and studies
published in other languages cannot be assessed. Second, as
most studies were conducted among Chinese, the general-
izability to other population needed to be further assessed.
Third, clinical heterogeneity may be detected as CM prepa-
rations, dose, and treatment duration are varied across the
included studies. Further studies are warranted to investigate
the effects of different CM preparations in treating middle
or late stage HCC. Fourth, sample size, selection criteria
of subjects, and TACE drugs varied across the included
studies, and the heterogeneity was not reflected in the
data analyses. Fifth, most of the studies did not report the
method of randomization, and all studies failed to report the
method of allocation concealment and blinding (subjective
outcomes), which might lead to the potential selection bias.
Moreover, reasons for dropouts and withdrawals were mostly
not described. Overall, these items were mostly at unclear or
high risk of bias which could bias the findings of this review
resulting in overestimation of the CMs beneficial effects.
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Table 3: The top 10 most frequently used CMs of the included studies.
CM herb Latin name (Chinese
Pinyin) No. TCM diagnosis Pharmacological properties
Radix Astragali (Huang Qi) 35 Qi deficiency
(1) Suppresses the oncogenic transformation of cancer cells [86]
(2) Induces apoptosis [87]
(3) Induces macrophage, LAK and NK cell activity [88, 89]
(4) Inhibits T-helper cell type 2 cytokines [89]
Poria Cocos (Fu Ling) 25 Dampness accumulation
(1) Induces apoptosis [90, 91]
(2) Cytotoxicity against cancer cell lines [90]
(3) Inhibits tumor angiogenesis [92]
Rhizoma Atractylodis
Macrocephalae (Bai Zhu) 23 Qi deficiency (1) Induces apoptosis [93, 94]
Radix Ginseng (Ren Shen) 19 Qi deficiency
(1) Induces apoptosis [95, 96]
(2) Inhibits tumor cell proliferation [96]
(3) Cytotoxicity against cancer cell lines [97, 98]
(4) Inhibits tumor angiogenesis [99]
Radix Bupleuri (Chai Hu) 19 Qi stagnation
(1) Induces apoptosis [100]
(2) Activates macrophages, NK and LAK cells [101]
(3) Downregulates TNF-𝛼, IL-6, and NF-𝜅B p65 expression [102]
Radix Codonopsis (Dang Shen) 18 Qi deficiency
(1) Inhibits cancer cells invasion and migration [103]
(2) Enhances T cell, B cell, and macrophage production, and activates
macrophages [104]
Semen Coicis (Yi Yi Ren) 15 Dampness accumulation
(1) Induces apoptosis [105]
(2) Inhibits NF-𝜅B signaling and protein kinase C activity [106]
(3) Stimulates T cell proliferation [107]
Herba Oldenlandia Diffusa (Bai
Hua She She Cao) 14 Fire toxin (1) Inhibits cancer cell proliferation and induces apoptosis [108, 109]
Radix Paeoniae Alba (Bai Shao) 13 Blood deficiency (1) Inhibits angiogenesis and induces apoptosis [110, 111]
Rhizoma Curcumae (E Zhu) 12 Blood stagnation
(1) Inhibits cancer cell proliferation and angiogenesis, induces cell
cycle arrest and apoptosis [112]
(2) Inhibits platelet aggregation [113]
CM: Chinese medicine; LAK: lymphokine activated killer; NF-𝜅B: nuclear factor kappa-light-chain enhancer of activated B cells; NK: natural killer; No.:
number of studies; TCM: traditional Chinese medicine; TNF-𝛼: tumor necrosis factor-alpha; IL: interleukin.
4.2. Implications for Practice and Research. As most included
studies have poor quality, future trials should be rigor-
ously implemented using standard procedures following a
standardized trial protocol (e.g., consolidated standards of
reporting trials statement) [117, 118]. Another crucial issue
is the quality control of CM preparations which consist of
various CMs from different batches. As different properties
of CMs might exist in different batches in the same CM
formula, the quality control of further CM preparations
should be established based on scientific practice including
chemical and bioresponse fingerprint to ensure the quality
and consistency of CM preparations and the validity of study
results [119, 120]. In addition, CMs should be provided by
a consistent and reliable supply to maintain the effective
treatment effect of CM preparations. Given that oral admin-
istration and intravenous injection of CMs were used by
all included studies, further reviews should compare the
effects between these routes. Moreover, as no data on the
possible interaction between TACE and CMs preparations
was reported, the interaction should be assessed further. Only
a small number of studies (33%) showed that the results of at
least 12-month survival (the long-term effectiveness) of CMs
treatment need to be determined in more RCTs with long-
term follow-up. Acute and subacute CMs-related side effects
in the studies were slight and alleviated spontaneously after
symptomatic treatment. However, these were only reported
in few studies (4%). Only short-termCMs-related side effects
were reported. And all the side effects were not measured
by standard criteria. Additional researches should evaluate
both acute and chronic CMs-related side effects according to
standard criteria to confirm the safety of CMs treatment in
treating patients with HCC.
5. Conclusion
The positive results in this meta-analysis show that CMs
treatment appears to increase the efficacy of TACE by pro-
longing survival, increasing tumor response, improving QoL,
and reducing TACE toxicity for unresectable HCC. Although
making a definitive recommendation is currently premature
with low quality of the most studies, these findings suggest
that CMs could be considered as an adjuvant therapy for
unresectable HCC patients during TACE treatment. RCTs
with rigorous methods, long-term follow-up, and standard
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reporting (consolidated standards of reporting trials state-
ment) are recommended to further evaluate the clinical
effects of combining CMs and TACE use for HCC patients
[117, 118].
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